Designing a biomedical cutter for heart valve leaflets

Vesalius心血管公司是一家设计和开发外科植入物和**二尖瓣关闭不全附件的生物医疗设备企业。**对于二尖瓣关闭不全且无法修复二尖瓣的患者，二尖瓣置换术**是必要的。目前的黄金标准治疗是外科二尖瓣置换术，一种心内直视手术。但由于心脏手术的风险，许多患者**不能得到安全的治疗，因此工业界正致力于经皮二尖瓣置换术，这**意味着通过导管而不是开放手术来替换二尖瓣。这项技术被称为**经导管二尖瓣置换术(TMVR)。**植入二尖瓣的尝试都有严重和常见的并发症**与称为左心室流出道梗阻(LVOTO)的技术有关，这是一种致命的并发症。**Vesalius的方法是复制手术以避免这个问题，但要经皮进行。在手术中，**通过将前叶与其在主动脉流出瓣旁边的附着物分开来避免这一问题。**Vesalius溶液是一种经皮工具，用于在二尖瓣前叶**产生精确的切割，然后通过该工具可以快速地将经导管瓣膜植入**用于产生切割的同一钢丝上。扩张的替换瓣膜使前叶远离主动脉流出瓣膜，从而避免了LVOTO。

Vesalius Cardiovascular is a biomedical device venture designing and developing surgical implants and**accessories for mitral valve regurgitation.**For patients with mitral regurgitation for whom mitral valve repair is not possible, mitral valve replacement**becomes necessary. The current gold standard therapy is surgical mitral valve replacement, an open-heart**operation. But because of the risk of heart surgery, many patients**cannot be safely treated, and so industry is working toward percutaneous mitral valve replacement, which**means the valve is replaced through a catheter rather than with open surgery. This technique is called**Transcatheter Mitral Valve Replacement (TMVR).**Attempts to implant a transcatheter mitral valve have all been subject to a serious and common complication**related to the technique called Left Ventricular Outflow Tract Obstruction (LVOTO), a fatal complication.**Vesalius approach is to replicate what is done surgically to avoid this problem, but percutaneously. At surgery,**the problem is avoided by dividing the anterior leaflet from its attachment beside the aortic outflow valve.**Vesalius solution is a percutaneous tool for the creation of a precise cut in the anterior leaflet of the mitral**valve, through which a transcatheter valve may then be expeditiously implanted over**the same wire that has been used to create the cut. The expanded replacement valve moves**the anterior leaflet away from the aortic outflow valve, and LVOTO is avoided.